These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17329706)

  • 1. Chronic kidney disease, anemia, and epoetin.
    Riley DS
    N Engl J Med; 2007 Mar; 356(9):956; author reply 958-9. PubMed ID: 17329706
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic kidney disease, anemia, and epoetin.
    Go AS; Ayus JC
    N Engl J Med; 2007 Mar; 356(9):957; author reply 958-9. PubMed ID: 17338046
    [No Abstract]   [Full Text] [Related]  

  • 3. Chronic kidney disease, anemia, and epoetin.
    Roger SD
    N Engl J Med; 2007 Mar; 356(9):958; author reply 958-9. PubMed ID: 17338047
    [No Abstract]   [Full Text] [Related]  

  • 4. Chronic kidney disease, anemia, and epoetin.
    Ashrani AA; Rajkumar SV
    N Engl J Med; 2007 Mar; 356(9):957-8; author reply 958-9. PubMed ID: 17338048
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic kidney disease, anemia, and epoetin.
    Mikhail A; Goldsmith D
    N Engl J Med; 2007 Mar; 356(9):956-7; author reply 958-9. PubMed ID: 17338045
    [No Abstract]   [Full Text] [Related]  

  • 6. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).
    Locatelli F; Covic A; Eckardt KU; Wiecek A; Vanholder R;
    Nephrol Dial Transplant; 2009 Feb; 24(2):348-54. PubMed ID: 19037082
    [No Abstract]   [Full Text] [Related]  

  • 7. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 8. Epoetin alfa: into the new millennium.
    Adamson JW
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):76-9. PubMed ID: 9671336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of anemia--payoffs and problems.
    Remuzzi G; Ingelfinger JR
    N Engl J Med; 2006 Nov; 355(20):2144-6. PubMed ID: 17108347
    [No Abstract]   [Full Text] [Related]  

  • 10. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ongoing study of anemia correction in chronic kidney disease.
    Pfeffer MA;
    N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
    [No Abstract]   [Full Text] [Related]  

  • 15. Epoetin alfa. Clinical evolution of a pleiotropic cytokine.
    Henry DH; Bowers P; Romano MT; Provenzano R
    Arch Intern Med; 2004 Feb; 164(3):262-76. PubMed ID: 14769622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
    J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.